Lung cancer remains the world’s leading cause of cancer death. Reducing tobacco use has helped, but it has not solved the problem. The disease is increasingly diagnosed in younger adults and in people who have never smoked, driven by exposures and biologic factors that are still only partly understood. Yet one truth remains unchanged: when stage I lung cancer is found early, survival climbs above 60%. With each advancing stage, that advantage narrows. The intervention that most consistently changes outcomes is not a new drug or a newly identified mutation. It is finding the cancer soon enough to treat it while cure is still possible. Everything else in this story begins there.

Lung Nodule Programs: The Infrastructure Behind Early Detection

The NELSON and NLST trials established that low-dose CT screening reduces lung cancer mortality. National screening rates have improved in recent years, but they remain far too low: a 2026 analysis found that only 24.5% of eligible U.S. adults were up to date on screening. The biggest opportunity today may not lie in formal screening programs alone. It may lie in incidental nodule follow-up, where many early-stage lung cancers first appear on scans ordered for other reasons and are then lost to follow-up.

One New York City lung nodule program recently reported tracking more than 1,000 referred nodules, including 616 discovered incidentally. Ninety-four patients were ultimately diagnosed with lung cancer, and 62.7% of those cancers were stage I. Without a system to track and close the loop, many of those patients likely would have disappeared into the gaps of routine care.

Virginia Mason Franciscan Health has seen a similar effect since launching its lung nodule program in 2023. After 943 referrals and 382 procedures, the program has identified cancer in 21.2% of referred patients, with detection rates rising noticeably after an interventional pulmonologist joined the team. These are patients who were found, evaluated, and treated—many of whom might otherwise have had a nodule mentioned in a report, with nowhere meaningful to go next.

The practical lesson is straightforward: any health system without a systematic lung nodule tracking program is missing patients who could still be cured. A spreadsheet is better than nothing. A dedicated lung nodule program is far better.

Technology: What Has Changed in Diagnosis and Staging

Robotic navigational bronchoscopy with cone-beam CT: Together, these tools have pushed diagnostic yield above 90%, making it possible to biopsy nodules as small as 5 mm. They also allow clinicians to reach peripheral nodules that once often required CT-guided transthoracic biopsy, a procedure with a higher risk of pneumothorax.

AI on chest X-ray: Programs can now flag concerning shadows on chest X-rays, including those taken in emergency departments, and prompt referral for low-dose CT screening. A patient who arrives with an unrelated complaint, undergoes a chest X-ray, and has a subtle density that might otherwise be overlooked now has another layer of detection. Early data suggest this approach can meaningfully improve lung cancer identification.

EBUS (endobronchial ultrasound): EBUS has largely replaced mediastinoscopy for mediastinal staging. In centers with established EBUS programs, mediastinoscopy is now rarely needed. It is less invasive, comparably informative in most staging scenarios, and can be performed during the same procedure as navigational bronchoscopy.

Lung-RADS standardized reporting: Standardized nodule reporting through Lung-RADS makes it easier to use AI-assisted language review of imaging reports to identify patients with actionable nodules. In institutions that have built this infrastructure, the path from an abnormal report to a patient referral can now be partially automated.

Surgical Approaches: Robotic Surgery Has Taken Over

The history of thoracic surgery is, in many ways, the history of making a punishing operation less punishing. Thoracotomy, the traditional open-chest approach, was painful, debilitating, and slow to recover from. Video-assisted thoracoscopic surgery (VATS) marked the first major leap forward. Now robotic thoracic surgery has become the dominant minimally invasive approach, reshaping what patients and surgeons expect from recovery.

In 2022, robotic thoracic surgery accounted for about 34% of minimally invasive lung resections in the United States. By 2026, that share had climbed to roughly 80%. The shift has been associated with shorter hospital stays, fewer complications, and better pain control. In programs with single-port robotic expertise, subcostal approaches—through the diaphragm rather than directly through the chest—offer the possibility of reducing postoperative pain even further.

Sublobar versus lobectomy for small tumors: For peripheral tumors smaller than 2 centimeters, wedge resection is now considered equivalent to anatomic lobectomy, provided a proper nodal dissection is performed. Guidelines published by CHEST in 2025 formalized that recommendation. The implication is important: patients who previously might not have qualified for resection because of limited pulmonary reserve or reduced performance status may now have a viable surgical option.

SBRT versus surgery: The Revised STARS trial reported similar outcomes for stereotactic body radiotherapy (SBRT) and surgery in peripheral tumors under 3 centimeters. Even so, the trial’s methodology remains debated, and overall survival still favors surgical resection. Surgery therefore remains the preferred option. For patients who cannot safely undergo an operation, SBRT remains a highly effective alternative.

Staging and Neoadjuvant Therapy

Several staging updates matter in current practice. T1 tumors with single-station N2 disease are now classified as stage IIB, a downstage from earlier systems. Neoadjuvant therapy is now part of the standard discussion for any tumor larger than 4 centimeters and is effectively required in current practice for patients with known N1 disease or more on PET or EBUS. The rationale is practical as well as biologic: neoadjuvant chemotherapy or chemo-immunotherapy can make surgery technically easier, create cleaner tissue planes around the tumor, and begin treating potential micrometastatic disease.

Molecular testing (NGS) for all eligible patients (Stage IB or greater) is now a standard part of the initial workup. Molecular results typically return within one to two weeks and should be ordered reflexively at the time of diagnosis rather than delayed until staging is complete.

Circulating Tumor DNA in Surgical Lung Cancer

Circulating tumor DNA is beginning to enter the surgical lung cancer landscape, especially in the neoadjuvant setting, where it may help assess treatment response before surgery and guide adjuvant therapy decisions. Its role, however, remains early and highly context-dependent. Assays are not yet standardized, and neither are the clinical frameworks for acting on the results. Still, it offers a glimpse of where the field is headed as neoadjuvant immunotherapy trials continue to mature.

For Patients and Referring Providers

If a lung nodule appears on any imaging study—whether on a screening CT, a chest X-ray, or an unrelated scan—do not let it drift without follow-up. Ask directly: “Is this being tracked in a lung nodule program? Who is responsible for follow-up?” The answers may determine whether a potentially curable cancer is caught early or first appears later as stage IV disease.

For patients who smoke, lung cancer screening is recommended by the USPSTF for adults ages 50 to 80 with a 20 pack-year smoking history who currently smoke or quit within the past 15 years. If you meet those criteria and have not had a low-dose CT scan, talk with your primary care clinician about getting one.

What to Remember

When stage I lung cancer is found early, survival exceeds 60%; early detection remains the most powerful intervention available.
Lung nodule programs provide the infrastructure that turns detection into treatment, especially through reliable follow-up of incidentally discovered nodules.
Robotic navigational bronchoscopy with cone-beam CT now achieves diagnostic yields above 90% for nodules as small as 5 mm.
Robotic thoracic surgery now accounts for roughly 80% of minimally invasive lung resections nationally and is associated with shorter hospital stays, fewer complications, and less pain.
For peripheral tumors under 2 centimeters, wedge resection with nodal dissection can expand surgical eligibility without compromising outcomes.
Neoadjuvant therapy is now standard in discussions of tumors larger than 4 centimeters and expected for known N1 or greater disease.
Screening rates remain far below where they should be, making incidental nodule programs one of the clearest opportunities to save more lives.

References

NLST Research Team. Reduced lung-cancer mortality with low-dose CT screening. New England Journal of Medicine, 2011.
de Koning HJ, et al. (NELSON trial). Reduced lung-cancer mortality with volume CT screening. New England Journal of Medicine, 2020.
Howington JA, et al. Guidelines for sublobar resection in peripheral lung cancer less than 2cm. CHEST, 2025.
STARS trial. SBRT vs surgery for stage I NSCLC. Lancet Oncology, 2015.
Lung nodule incidental detection program outcomes. Journal of Thoracic Oncology, 2026.
Templin T. "Early-Stage Non-Small Cell Lung Cancer." Presented at the 2026 Alaska Hematology Oncology Conference, Anchorage, AK, May 2026.